Form 4: Century Therapeutics SVP Douglas Carr Reports Stock Transactions

Douglas Carr, SVP Finance & Operations at Century Therapeutics, reports the sale of shares to cover tax obligations and the grant of restricted stock units.

Summary

• Douglas Carr, SVP Finance & Operations at Century Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 10, 2025, Carr sold 1,240 shares of common stock at $0.615 per share to cover tax withholding obligations related to vesting restricted stock units.
• On March 11, 2025, Carr was granted 95,625 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Century Therapeutics common stock.
• The RSUs vest 25% on March 11, 2026, and the remaining 75% vest quarterly over the following three years, contingent upon continued service.
• Carr also received a stock option (right to buy) for 95,625 shares at an exercise price of $0.601.
• The option vests 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The RSUs vest 25% on March 11, 2026, with the remaining 75% vesting on a quarterly basis for the three years thereafter, subject to continued service. The stock options vest 25% on March 11, 2026, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Stakeholder Impact

• The stock sale has a minor dilutive effect on existing shareholders.
• The RSU and stock option grants incentivize the executive to perform well, potentially benefiting shareholders.

Key Dates